| Literature DB >> 23554812 |
Inder Sehgal1, Wallace D Winters, Michael Scott, Andrew David, Glenn Gillis, Thaya Stoufflet, Anand Nair, Konstantine Kousoulas.
Abstract
Aloe vera, a common ingredient in cosmetics, is increasingly being consumed as a beverage supplement. Although consumer interest in aloe likely stems from its association with several health benefits, a concern has also been raised by a National Toxicology Program Report that a nondecolorized whole leaf aloe vera extract taken internally by rats was associated with intestinal mucosal hyperplasia and ultimately malignancy. We tested a decolorized whole leaf (DCWL) aloe vera, treated with activated charcoal to remove the latex portion of the plant, for genotoxicity in bacteria, acute/subacute toxicity in B6C3F1 mice, and subchronic toxicity in F344 rats. We found this DCWL aloe vera juice to be nongenotoxic in histidine reversion and DNA repair assays. Following acute administration, mice exhibited no adverse signs at 3- or 14-day evaluation periods. When fed to male and female F344 rats over 13 weeks, DCWL aloe led to no toxicity as assessed by behavior, stools, weight gain, feed consumption, organ weights, and hematologic or clinical chemistry profiles. These rats had intestinal mucosal morphologies-examined grossly and microscopically-that were similar to controls. Our studies show that oral administration of this DCWL aloe juice has a different toxicology profile than that of the untreated aloe juice at exposures up to 13 weeks.Entities:
Year: 2013 PMID: 23554812 PMCID: PMC3608129 DOI: 10.1155/2013/802453
Source DB: PubMed Journal: J Toxicol ISSN: 1687-8191
Figure 1Effects of DCWL aloe vera juice on DNA damage repair. Absorbance reflects measurement of SOS transgene (β-galactosidase) induction and subsequent substrate conversion. Symbols represent means of triplicate wells incubated in the absence or presence of S9 rat liver extract. Error bars represent standard deviations.
Selected organ weights of B6C3F1 mice administered aloe juice by gavage.
| 3 days post aloe | Male control | Aloe male | Control female | Aloe female |
|---|---|---|---|---|
| Mortalities | 0/6 | 0/6 | 0/6 | 0/6 |
| Abnormal clinical signs | 0/6 | 0/6 | 0/6 | 0/6 |
| Gross abnormalities | 0/6 | 0/6 | 0/6 | 0/6 |
| Weight change % init. b.wt. | 0.115 ± 1.03 | 0.868 ± 2.15 | 4.12 ± 2.83 | 3.87 ± 2.05 |
| Relative organ weight | ||||
| Liver relative weight | 4.58 ± 0.240 | 4.35 ± 0.113 | 5.01 ± 0.173 | 4.97 ± 0.315 |
| Kidney (rt) | 0.769 ± 0.072 | 0.750 ± 0.029 | 0.724 ± 0.047 | 0.679 ± 0.048 |
| Heart | 0.460 ± 0.046 | 0.473 ± 0.044 | 0.480 ± 0.025 | 0.498 ± 0.056 |
| Lung | 0.592 ± 0.088 | 0.578 ± 0.062 | 0.667 ± 0.033 | 0.663 ± 0.069 |
| Testicle (rt) | 0.390 ± 0.044 | 0.371 ± 0.017 | — | — |
|
| ||||
| 14 days post aloe | ||||
|
| ||||
| Mortalities | 0/6 | 0/6 | 0/6 | 0/6 |
| Abnormal clinical signs | 0/6 | 0/6 | 0/6 | 0/6 |
| Gross abnormalities | 0/6 | 0/6 | 0/6 | 0/6 |
| Weight Change % init. b.wt. | 3.36 ± 2.91 | 6.37 ± 0.772 | 7.18 ± 2.65 | 6.85 ± 3.46 |
| Relative organ weight | ||||
| Liver | 4.85 ± 0.252 | 4.65 ± 0.108 | 5.21 ± 0.372 | 4.74 ± 0.388 |
| Kidney (rt) | 0.769 ± 0.072 | 0.750 ± 0.029 | 0.724 ± 0.047 | 0.679 ± 0.048 |
| Heart | 0.487 ± 0.077 | 0.442 ± 0.037 | 0.585 ± 0.063 | 0.482 ± 0.061 |
| Lung | 0.633 ± 0.080 | 0.614 ± 0.650 | 0.725 ± 0.075 | 0.662 ± 0.053 |
| Testicle (rt) | 0.390 ± 0.044 | 0.371 ± 0.017 | — | — |
Values presented as mean ± s.d.
Relative organ weights are expressed as a percent of body weight.
Hematology of whole blood from B6C3F1 mice administered aloe juice by gavage.
| Parameters—3 days post exposure | Control male | Aloe male | Control female | Aloe female |
|---|---|---|---|---|
| RBC (106/uL) | 8.6 ± 0.21 | 8.8 ± 0.18 | 8.7 ± 0.26 | 8.8 ± 0.25 |
| Hb (g/dL) | 13.1 ± 0.33 | 13.4 ± 0.28 | 13.3 ± 0.33 | 13.4 ± 0.31 |
| HCT (%) | 43.5 ± 1.29 | 44.1 ± 1.16 | 43.2 ± 1.34 | 42.9 ± 1.21 |
| RDW (%) | 12.7 ± 0.45 | 12.7 ± 0.30 | 12.3 ± 0.46 | 11.9 ± 0.36 |
| MCV (fL) | 50.4 ± 0.48 | 50.2 ± 0.86 | 49.6 ± 0.30 | 48.7 ± 0.44* |
| MCH (fL) | 15.2 ± 0.04 | 15.3 ± 0.18 | 15.4 ± 0.18 | 15.2 ± 0.16 |
| MCHC (g/dL) | 30.1 ± 0.23 | 30.4 ± 0.32 | 31.0 ± 0.43 | 31.2 ± 0.27* |
| Platelets (103/uL) | 1100.0 ± 102.10 | 1116.8 ± 129.31 | 952.2 ± 128.94 | 1041.7 ± 128.75 |
| WBC's (103/uL) | 2.2 ± 1.02 | 3.3 ± 2.86 | 2.1 ± 0.92 | 2.3 ± 0.58 |
|
| ||||
| Parameters—14 days post exposure | ||||
|
| ||||
| RBC (106/uL) | 8.7 ± 0.32 | 8.7 ± 0.27 | 8.4 ± 0.28 | 8.7 ± 0.35 |
| Hb (g/dL) | 13.2 ± 0.39 | 13.1 ± 0.41 | 13.1 ± 0.64 | 13.6 ± 0.42 |
| HCT (%) | 44.7 ± 2.03 | 43.8 ± 1.21 | 42.7 ± 0.87 | 43.3 ± 1.48 |
| RDW (%) | 13.0 ± 0.43 | 13.2 ± 0.64 | 14.0 ± 3.53 | 12.2 ± 0.71 |
| MCV (fL) | 51.0 ± 0.75 | 50.2 ± 0.45* | 51.7 ± 3.54 | 49.6 ± 0.28 |
| MCH (fL) | 15.1 ± 0.18 | 15.0 ± 0.08 | 15.8 ± 0.19 | 15.6 ± 0.14 |
| MCHC (g/dL) | 29.5 ± 0.50 | 29.8 ± 0.36 | 30.6 ± 1.6 | 31.5 ± 0.14 |
| Platelets (103/uL) | 1068.8 ± 129.2 | 1100.0 ± 104.5 | 955.2 ± 310.53 | 1023.5 ± 16.2 |
| WBC's (103/uL) | 4.2 ± 1.5 | 3.8 ± 1.1 | 3.1 ± 2.3 | 2.4 ± 0.42 |
Values expressed as mean ± s.d.
*P ≤ 0.05.
RBC: red blood cell count; Hb: hemoglobin; HCT: hematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; WBC: total white blood cell count; RDW: red blood cell distribution width; MCHC: mean corpuscular hemoglobin concentration; WBC's: white blood cell count.
Clinical chemistry of plasma from B6C3F1 mice administered aloe juice by gavage.
| Parameters—3 days post exposure | Control male | Aloe male | Control female | Aloe female |
|---|---|---|---|---|
| ALT (U/L) | 26.0 ± 3.5 | 23.0 ± 5.4 | 18.4 ± 2.0 | 19.7 ± 2.2 |
| ALP (U/L) | 64.2 ± 4.4 | 60.56 ± 7.3 | 87.8 ± 9.4 | 88.8 ± 16.4 |
| CK (U/L) | 287.6 ± 264.8 | 146.0 ± 114.7 | 85.4 ± 29.2 | 120.2 ± 68.3 |
| TBIL (mg/dL) | ≤0.1# | ≤0.1 | ≤0.1 | ≤0.1 |
| Total protein | 4.5 ± 0.23 | 4.3 ± 0.1* | 4.1 ± 0.13 | 4.0 ± 0.42 |
| BUN (mg/dL) | 18.0 ± 1.2 | 18.0 ± 1.4 | 22.8 ± 1.9 | 22.5 ± 1.1 |
| Creatinine (mg/dL) | ≤0.2# | ≤0.2 | ≤0.2 | ≤0.2 |
|
| ||||
| Parameters—14 days post exposure | ||||
|
| ||||
| ALT (U/L) | 25.2 ± 7.4 | 21.8 ± 6.5 | 23.2 ± 11.9 | 18.7 ± 2.4 |
| ALP (U/L) | 71.2 ± 18.0 | 67.4 ± 5.0 | 101.3 ± 3.9 | 86.2 ± 16.6 |
| CK (U/L) | 117.0 ± 14.3 | 169.2 ± 86.9 | 157.2 ± 105.5 | 196.0 ± 144.6 |
| TBIL (mg/dL) | ≤0.1# | ≤0.1 | ≤0.1 | ≤0.1 |
| Total protein | 3.8 ± 0.06 | 4.0 ± 0.3 | 3.8 ± 0.03 | 3.8 ± 0.2 |
| BUN (mg/dL) | 20.8 ± 4.0 | 21.8 ± 2.6 | 24.3 ± 2.3 | 22.2 ± 1.0 |
| Creatinine (mg/dL) | ≤0.2# | ≤0.2 | ≤0.2 | ≤0.2 |
Values expressed as mean ± s.d.
*P ≤ 0.05.
ALT: alanine aminotransferase activity; ALP: alkaline phosphatase Activity; CK: creatine kinase; TBIL: total bilirubin; BUN: blood urea nitrogen.
#Levels for TBIL and creatinine were at or below instrument quantitation threshold.
Figure 2Weekly body weights of male and female rats fed DCWL aloe vera diet over 13 weeks. The symbols represent mean values for control and aloe-fed groups error bars show standard deviations.
Figure 3Weekly feed consumption of male and female rats fed DCWL aloe vera diet over 13 weeks. The symbols represent mean values for control and aloe-fed groups error bars show standard deviations.
The effect of aloe vera administration for 13 weeks on rat organ weights.
| Parameter | Male control | WL aloe male | Control female | WL aloe female 13 week |
|---|---|---|---|---|
| Mortalities | 0/7 | 0/7 | 0/6 | 0/7 |
| Abnormal clinical signs | 0/7 | 0/7 | 1/6 | 0/7 |
| Gross abnormalities at necropsy | 0/7 | 0/7 | 0/6 | 0/7 |
| % body weight change | 190.3 ± 6.63 | 177.5 ± 23.10 | 143.6 ± 5.82 | 144.4 ± 10.74 |
| Relative organ weight | ||||
| Liver | 3.76 ± 0.233 | 3.82 ± 0.178 | 3.30 ± 0.103 | 3.28 ± 0.164 |
| Kidney (rt) | 0.338 ± 0.059 | 0.374 ± 0.070 | 0.334 ± 0.045 | 0.328 ± 0.072 |
| Kidney (lf) | 0.334 ± 0.077 | 0.412 ± 0.098 | 0.352 ± 0.049 | 0.336 ± 0.061 |
| Heart | 0.325 ± 0.034 | 0.294 ± 0.050 | 0.419 ± 0.051 | 0.376 ± 0.044 |
| Lung | 0.490 ± 0.081 | 0.550 ± 0.080 | 0.540 ± 0.059 | 0.497 ± 0.082 |
All values expressed as mean ± standard deviation.
*P ≤ 0.05 compared with gender control.
Relative organ weights are expressed as a percent of body weight.
The effect of aloe vera administration for 13 weeks on rat hematologies.
| Parameter | Control male | WL aloe male | Control female | WL aloe female |
|---|---|---|---|---|
| RBC (106/uL) | 7.95 ± 0.28 | 8.28 ± 0.34 | 7.26 ± 0.59 | 6.94 ± 0.42 |
| Hgb (g/dL) | 12.54 ± 0.32 | 12.94 ± 0.50 | 12.32 ± 0.20 | 11.80 ± 0.71 |
| HCT (%) | 38.76 ± 1.13 | 40.09 ± 1.33 | 37.68 ± 1.21 | 35.83 ± 1.97 |
| RDW (%) | 12.99 ± 0.30 | 12.89 ± 0.11 | 8.10 ± 5.08 | 11.29 ± 0.33 |
| MCV (fL) | 48.73 ± 0.54 | 48.66 ± 0.59 | 51.05 ± 0.67 | 51.60 ± 0.97 |
| MCH (fL) | 15.79 ± 0.22 | 15.73 ± 0.14 | 16.67 ± 0.45 | 17.00 ± 0.77 |
| MCHC (g/dL) | 32.40 ± 0.23 | 32.99 ± 0.37 | 32.67 ± 0.58 | 32.94 ± 0.52 |
| Platelets (103/uL) | 613.43 ± 48.41 | 586.57 ± 66.12 | 569.17 ± 84.41 | 564.43 ± 61.43 |
| MPV (fL) | 7.67 ± 0.61 | 7.40 ± 0.13 | 7.72 ± 0.30 | 7.99 ± 0.51 |
| Plasma protein (g/dL) | 7.56 ± 0.61 | 12.03 ± 13.22 | 6.80 ± 0.46 | 6.47 ± 0.69 |
| PCV (%) | 38.43 ± 1.13 | 39.29 ± 1.60 | 36.17 ± 0.98 | 34.71 ± 1.60 |
| WBC's (103/uL) | 4.73 ± 0.56 | 5.17 ± 1.19 | 3.42 ± 0.53 | 3.07 ± 1.09 |
| Neutrophils (%) | 0.89 ± 0.27 | 0.93 ± 0.24 | 0.52 ± 0.10 | 0.61 ± 0.23 |
| Lymphocytes (%) | 3.59 ± 0.69 | 3.96 ± 0.95 | 2.67 ± 0.49 | 2.31 ± 0.90 |
| Monocytes (%) | 0.14 ± 0.05 | 0.21 ± 0.11 | 0.15 ± 0.05 | 0.13 ± 0.10 |
| Eosinophils (%) | 0.07 ± 0.05 | 0.06 ± 0.05 | 0.03 ± 0.05 | 0.04 ± 0.05 |
All values expressed as mean ± standard deviation.
*P ≤ 0.05 compared with gender control.
The effect of aloe vera administration for 13 weeks on rat clinical chemistires.
| Parameter | Control male | WL aloe male | Control female | WL aloe female |
|---|---|---|---|---|
| Glucose (mg/dL) | 221.0 ± 36.13 | 200.7 ± 59.92 | 190.3 ± 8.26 | 168.9 ± 34.28 |
| AST (U/L) | 61.14 ± 14.50 | 62.33 ± 8.45 | 71.17 ± 18.98 | 68.14 ± 12.27 |
| ALT (U/L) | 35.29 ± 5.22 | 41.67 ± 13.95 | 29.33 ± 10.29 | 25.86 ± 4.45 |
| ALP (U/L) | 147.0 ± 15.77 | 152.8 ± 5.91 | 167.17 ± 12.58 | 150.43 ± 28.81 |
| CK (U/L) | 190.43 ± 113.15 | 353.00 ± 380.35 | 204.50 ± 72.02 | 235.29 ± 132.17 |
| Total protein (g/dL) | 5.81 ± 0.47 | 6.02 ± 0.43 | 5.67 ± 0.45 | 5.25 ± 0.52 |
| Albumin (g/dL) | 3.06 ± 0.24 | 3.07 ± 0.16 | 3.23 ± 0.27 | 2.88 ± 0.23* |
| Globulin (g/dL) | 2.76 ± 0.26 | 2.95 ± 0.28 | 2.42 ± 0.23 | 2.37 ± 0.31 |
| Cholesterol (mg/dL) | 103.7 ± 17.21 | 94.83 ± 6.85 | 102.8 ± 9.95 | 84.00 ± 12.81* |
| BUN (mg/dL) | 21.29 ± 2.06 | 20.17 ± 1.60 | 17.33 ± 7.94 | 18.86 ±1.46 |
| Creatinine (mg/dL) | 0.31 ± 0.035 | 0.32 ± 0.032 | 0.34 ± 0.02 | 0.30 ± 0.03 |
| Calcium (mg /dL) | 8.99 ± 0.69 | 9.37 ± 0.67 | 8.25 ± 1.26 | 7.46 ± 0.94 |
| Phosphorus (mg/dL) | 3.89 ± 0.41 | 4.00 ± 0.44 | 3.57 ± 0.38 | 3.03 ± 0.55 |
| Sodium (mmol/L) | 141.1 ± 1.22 | 140.7 ± 1.51 | 140.6 ± 1.97 | 142.1 ± 1.57 |
| Potassium (mmol/L) | 3.24 ± 0.30 | 3.50 ± 0.18 | 2.75 ± 0.14 | 2.59 ± 0.20 |
| Chloride (mmol/L) | 103.3 ± 3.15 | 101.8 ± 2.32 | 106.2 ± 2.14 | 110.6 ± 4.61 |
| Bicarbonate (mmol/L) | 25.00 ± 2.00 | 26.57 ± 2.70 | 23.2 ± 3.63 | 20.49 ± 2.68 |
| Anion gap (mmol/L) | 16.11 ± 1.50 | 15.77 ± 0.77 | 13.73 ± 1.67 | 13.67 ± 1.51 |
All values expressed as mean ± standard deviation. *P ≤ 0.05 compared with gender control.
Consumption of Aloe vera by rats in this study versus NTP drinking water study.
| Doses of aloe | Target malic acid concentration | Malic acid molarity in dosed form (mM) | Consumption of dosed form (g/day)* | Weight of rats at 4 weeks (g)* | umol/day malic acid consumed/100 g body weight |
|---|---|---|---|---|---|
| NTP 1% in water | 1980 (ppm) | 14.8 | 28.80 male | 200.0 male | 212.8 male |
| Present study 100 g/kg | 36.2 mmol/kg feed | 37.8# | 14.30 male | 239.0 male | 235.0 male |
∓Taken from Table H4, Target values for malic acid administered to rats in the 2-year study at approximately 4 weeks, pg. 260 NTP study.
Measured in Aloe feed extract.
*NTP data obtained from Tables J1 and J2, pgs. 283 and 284 NTP study.
#Assumes 1 gram feed = 1 ml solid.
(a)
| Sample | No. of positive wells @ 2 days | No. of positive wells @ 3 days | No. of positive wells @ 4 days | No. of positive wells @ 5 days |
|---|---|---|---|---|
| Blank without S9 | 0 | 3 | 3 | 5 |
| Blank + S9 | 0 | 3 | 11 | 16 |
| WL Aloe 21x | 0 | 0 | 0 | 0 |
| WL Aloe 21x + S9 | 0 | 2 | 0 | 0 |
| WL Aloe 14x | 0 | 0 | 0 | 0 |
| WL Aloe 14x + S9 | 0 | 0 | 0 | 10 |
| WL Aloe 7x | 0 | 2 | 4 | 9 |
| WL Aloe 7x + S9 | 0 | 0 | 1 | 6 |
| WL Aloe 7x + 2x S9 | 0 | 2 | 3 | 8 |
@ indicates at.
(b)
| Sample | No. of positive wells @ 2 days | No. of positive wells @ 3 days | No. of positive wells @ 4 days | No. of positive wells @ 5 days |
|---|---|---|---|---|
| Blank without S9 | 0 | 0 | 1 | 2 |
| Blank + S9 | 0 | 3 | 17 | 20 |
| WL Aloe 21x | 0 | 0 | 0 | 3 |
| WL Aloe 21x + S9 | 0 | 0 | 15 | 17 |
| WL Aloe 14x | 0 | 0 | 2 | 4 |
| WL Aloe 14x + S9 | 0 | 0 | 14 | 16 |
| WL Aloe 7x | 0 | 0 | 0 | 0 |
| WL Aloe 7x + S9 | 0 | 0 | 3 | 11 |
| WL Aloe 7x + 2x S9 | 0 | 0 | 10 | 15 |